WHAT IS THE PLAC® Test?
The PLAC® Test measures Lp-PLA2, a vascular specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiac events.
Increased levels of Lp-PLA2 increase your risk of having a heart attack or stroke.
The PLAC® Test is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. 87% of strokes are ischemic1. 68% of all heart attacks and strokes occur from clots, not from narrowing of the arteries.
As reported in the Framingham Heart Study, 50% of cardiovascular events occur in patients with unremarkable lipid levels, highlighting the prevalence of hidden cardiovascular risk. In addition, since LDL has proven not to be a reliable predictor of stroke, the PLAC Test addresses this important unmet clinical need.
This simple blood test, now available to run on popular clinical chemistry analysers, can help you identify those patients who would benefit from more aggressive treatment.
The automated PLAC® Test is FDA and CE mark approved.
The PLAC® Test for Lp-PLA2 is the only blood test that helps identify hidden risk for heart attack and stroke. Early detection and more aggressive treatment can help prevent these cardiovascular events.
1Source: CDC, AHA Statistical Update 2007